REGARDING THE PROCUREMENT OF INSULIN GLARGIN

According to the legislation, medicines and medical devices are purchased by the Single Distributor under the international non-proprietary name. Lantus and Basalog are trade names,the international non-proprietary name is Insulin glargine.

In addition, one of the requirements for purchased medicines and medical devices to participate in the procurement procedures is the presence of state registration in the Republic of Kazakhstan, which is issued only upon confirmation of the quality, efficacy and safety of medicines and medical devices.

Quality issues of medicines and medical devices circulating on the market of Kazakhstan are within the competence of the authorized body and the National Center for Expertise of Medicinal Products, which registers them, allows them to be admitted to the market, based on various examinations, and is confirmed by a certificate of conformity.

The use of generics and biosimilars is a global practice that makes it possible to increase the availability of medicines to reach a larger population.

Since 2021, under a long-term agreement with a domestic manufacturer, a biosimilar medicine manufactured by the Karaganda Pharmaceutical Complex, under the trade name RingGlar®, has been procuring.

Also, a system for monitoring, analyzing and evaluating information on the safety of registered medicines and medical devices has been introduced in Kazakhstan.

If an adverse reaction or ineffectiveness of medicines and medical devices in the treatment of a disease is detected, patients should contact their doctor to fill out a yellow card-message on the website of the Center of Expertise www.ndda.kz.

All cards received by the Center of Expertise are subject to careful analysis. All factors are being checked, samples of medicines and medical devices are being withdrawn and laboratory tests are being carried out in specialized centers of the National Center for Expertise of Medicines. Based on the results of the examination, the regulatory authority decides to suspend the series or the entire registration certificate. Monitoring covers all regions and is carried out in accordance with international standards.

The practice of "yellow cards" is primarily intended to ensure the safety of patients, it is such feedback tools that contribute to the development of a patient-centered healthcare system.

According to the National Center for Expertise of Medicinal Products, there were no yellow cards for RinGlar® in 2021.

As the situation that has developed in recent years, in particular with the intensification of the Covid-19 pandemic, as well as the geopolitical crisis in the world, shows, it is possible to uninterruptedly provide the country with medicines only if there is domestic production. Today, Kazakhstan has launched the production of world-class pharmaceutical products, including those procured for free provision of the population with diabetes and other nosologies.